Showing 1371-1380 of 1614 results for "".
- Improved PC-IOL Technology is Key to Recent and Future Premium Cataract Surgery Growthhttps://modernod.com/news/improved-pc-iol-technology-is-key-to-recent-and-future-premium-cataract-surgery-growth/2481273/Presbyopia-correcting IOL technology improvements have led to almost a doubling of global units over the past 5 years and will be critical to driving future growth over the next 5 years, according to a Market Scope report. In 2022, PC-IOLs will represent nearly 55 percent of premi
- Alcon Completes Acquisition of Aerie Pharmaceuticalshttps://modernod.com/news/alcon-completes-acquisition-of-aerie-pharmaceuticals/2481258/Alcon announced that it has completed its acquisition of Aerie Pharmaceuticals. In August, Alcon announced its was acquiring Aerie for about $770 million, or $15.25 per share—a premium of 37% to Aerie’s closing price prior to the deal. The deal bolsters Alcon's
- AEYE Health Receives FDA Clearance for AI-Based Autonomous Screening for Referable Diabetic Retinopathyhttps://modernod.com/news/aeye-health-receives-fda-clearance-for-ai-based-autonomous-screening-for-referable-diabetic-retinopathy/2481245/AEYE Health announced that it received a 510(k) clearance from the FDA to market its diagnostic screening system for diabetic retinopathy. Screening diabetics for retinopathy using AI has recently become reimbursable in the United States using the newly approved CPT
- Harrow Launches Atropine.comhttps://modernod.com/news/harrow-launches-atropinecom/2481236/Harrow announced the launch of atropine.com, an ordering and marketing portal designed specifically for prescribers interested in compounded atropine formulations. All atropine.com, prescriptions will be dispensed through Harrow’s wholly owned
- Nicox Outlines Future Development and Partnering Plans for NCX 470https://modernod.com/news/nicox-outlines-future-development-and-partnering-plans-for-ncx-470-in-glaucoma/2481228/Nicox SA announced future development and partnering plans for NCX 470, a novel nitric oxide (NO)-donating bimatoprost eye drop, currently in phase 3 development for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension. “Our market research&nbs
- Nanodropper Launches 2022 Give the Gift of Vision Campaign to Support Global Access to Eye Carehttps://modernod.com/news/nanodropper-launches-2022-give-the-gift-of-vision-campaign-to-support-global-access-to-eye-care/2481193/Nanodropper launched its "2022 Give the Gift of Vision" program, an effort to donate 1,000 Nanodropper adaptors to at-need patients in the United States and its global nonprofit partners—designed to deliver better access to vision-saving care in low resource settings in
- Santen Filing Accepted by EMA for Review of Application for STN1013001 Cationic Emulsion of Latanoprost 50μg/mL in Glaucomahttps://modernod.com/news/santen-filing-accepted-by-ema-for-review-of-application-for-stn1013001-cationic-emulsion-of-latanoprost-50mgml-in-glaucoma/2481157/Santen Pharmaceutical announced European Medicines Agency (EMA) acceptance for review of a marketing authorization application for the use of STN1013001 for lowering of IOP in open-angle glaucoma and ocular hypertension. STN1013001 is preservative-free latanoprost 50μg/mL p
- Ocuphire Expands Medical Advisory Board with Seven New KOLs; Expands Leadership Teamhttps://modernod.com/news/ocuphire-expands-medical-advisory-board-with-seven-new-kols-expands-leadership-team/2481132/Ocuphire Pharma announced that it has appointed seven new key opinion leaders (KOLs) across retina, cornea/refractive, and medical optometry to its Medical Advisory Board (MAB). In addition, Ronil Patel, MS, has been promoted to Vice President, Business Development and Market St
- BVI Announces Certification for its IOL Portfolio Under the European Medical Device Regulationhttps://modernod.com/news/bvi-announces-certification-for-its-iol-portfolio-under-the-european-medical-device-regulation/2481094/BVI announced certification for its IOL portfolio under the European Medical Device Regulation (MDR, (EU) 2017/745) from its Notified Body, the British Standards Institution (BSI)¹. The new regulatory criteria came into effect in May 2021, replacing the prior Medica
- New MaximEyes.com Software Designed to Simplify EHR Navigation and Patient Flowhttps://modernod.com/news/new-maximeyescom-software-designed-to-simplify-ehr-navigation-and-patient-flow/2481076/First Insight has introduced MaximEyes.com, which is desinged go allow eye care processionals to access data—anywhere, anytime, from any device—in a web browser or via a local server.